AveXis wants $400M more for promising SMA gene therapy; ShangPharma partners with Icahn School of Medicine at Mount Sinai
→ AveXis $AVXS is raising more cash to fuel its gene therapy for spinal muscular atrophy with a public offering of up to $400 million …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
